240 related articles for article (PubMed ID: 15627916)
1. Optimizing treatment of chronic decompensated heart failure in the outpatient setting.
Silver MA
Rev Cardiovasc Med; 2004; 5 Suppl 4():S28-36. PubMed ID: 15627916
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effects of early initiation of vasoactive agents in patients with acute decompensated heart failure.
Saltzberg MT
Rev Cardiovasc Med; 2004; 5 Suppl 4():S17-27. PubMed ID: 15627915
[TBL] [Abstract][Full Text] [Related]
3. Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF).
Ezekowitz JA; Hernandez AF; Starling RC; Yancy CW; Massie B; Hill JA; Krum H; Diaz R; Ponikowski P; Metra M; Howlett JG; Gennevois D; O'Connor CM; Califf RM; Fonarow GC
Am Heart J; 2009 Feb; 157(2):219-28. PubMed ID: 19185628
[TBL] [Abstract][Full Text] [Related]
4. Nesiritide for the treatment of decompensated heart failure.
Wylie JV; Tsao L
Expert Rev Cardiovasc Ther; 2004 Nov; 2(6):803-13. PubMed ID: 15500426
[TBL] [Abstract][Full Text] [Related]
5. Controversy and conflict in the treatment of acute decompensated heart failure: nesiritide as evidence-based treatment.
Munger MA; Ng TM; Van Tassell BW
Pharmacotherapy; 2007 May; 27(5):619-25. PubMed ID: 17461695
[TBL] [Abstract][Full Text] [Related]
6. Nesiritide: trials and tribulations.
Arora RR
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):165-9. PubMed ID: 17056828
[TBL] [Abstract][Full Text] [Related]
7. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE).
Abraham WT; Adams KF; Fonarow GC; Costanzo MR; Berkowitz RL; LeJemtel TH; Cheng ML; Wynne J; ;
J Am Coll Cardiol; 2005 Jul; 46(1):57-64. PubMed ID: 15992636
[TBL] [Abstract][Full Text] [Related]
8. Nesiritide: practical guide to its safe and effective use.
Fonarow GC
Rev Cardiovasc Med; 2001; 2 Suppl 2():S32-5. PubMed ID: 12439360
[TBL] [Abstract][Full Text] [Related]
9. Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction.
Riter HG; Redfield MM; Burnett JC; Chen HH
J Am Coll Cardiol; 2006 Jun; 47(11):2334-5. PubMed ID: 16750705
[No Abstract] [Full Text] [Related]
10. Nesiritide: a unique therapeutic cardiac peptide.
Rayburn BK; Bourge RC
Rev Cardiovasc Med; 2001; 2 Suppl 2():S25-31. PubMed ID: 12439359
[TBL] [Abstract][Full Text] [Related]
11. Intermittent outpatient nesiritide infusion reduces hospital admissions in patients with advanced heart failure.
Schwarz ER; Najam S; Akel R; Sulimanjee N; Bionat S; Rosanio S
J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):232-6. PubMed ID: 17875951
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF).
Hernandez AF; O'Connor CM; Starling RC; Reist CJ; Armstrong PW; Dickstein K; Lorenz TJ; Gibler WB; Hasselblad V; Komajda M; Massie B; McMurray JJ; Nieminen M; Rouleau JL; Swedberg K; Califf RM
Am Heart J; 2009 Feb; 157(2):271-7. PubMed ID: 19185633
[TBL] [Abstract][Full Text] [Related]
13. The benefits of early vasoactive therapy in the treatment of acute decompensated heart failure.
Albert NM
J Am Acad Nurse Pract; 2005 Oct; 17(10):403-10. PubMed ID: 16181262
[TBL] [Abstract][Full Text] [Related]
14. Effect of nesiritide on renal function in patients admitted for decompensated heart failure.
Arora S; Clarke K; Srinivasan V; Gradman A
QJM; 2007 Nov; 100(11):699-706. PubMed ID: 17971392
[TBL] [Abstract][Full Text] [Related]
15. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure.
Arnold LM; Crouch MA; Carroll NV; Oinonen MJ
Pharmacotherapy; 2006 Aug; 26(8):1078-85. PubMed ID: 16863484
[TBL] [Abstract][Full Text] [Related]
16. Administration of a large nesiritide bolus dose in a pediatric patient: case report and review of nesiritide use in pediatrics.
Moffett BS; Jefferies JL; Price JF; Clunie S; Denfield S; Dreyer WJ; Towbin JA
Pharmacotherapy; 2006 Feb; 26(2):277-80. PubMed ID: 16466333
[TBL] [Abstract][Full Text] [Related]
17. Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial).
Yancy CW; Saltzberg MT; Berkowitz RL; Bertolet B; Vijayaraghavan K; Burnham K; Oren RM; Walker K; Horton DP; Silver MA
Am J Cardiol; 2004 Sep; 94(5):595-601. PubMed ID: 15342289
[TBL] [Abstract][Full Text] [Related]
18. Nesiritide: harmful or harmless?
Dorsch MP; Rodgers JE
Pharmacotherapy; 2006 Oct; 26(10):1465-78. PubMed ID: 16999657
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of nesiritide for the treatment of decompensated heart failure.
Emerman CL
Rev Cardiovasc Med; 2002; 3 Suppl 4():S28-34. PubMed ID: 12439428
[TBL] [Abstract][Full Text] [Related]
20. Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow-Up Serial Infusions of Nesiritide [FUSION I] trial).
Yancy CW; Singh A
Am J Cardiol; 2006 Jul; 98(2):226-9. PubMed ID: 16828598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
